Effect of Melatonin on Multiple Sclerosis Related Fatigue
NCT01718678 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44
Last updated 2012-10-31
Summary
The purpose of this study was to evaluate the efficacy and safety of Melatonin in treatment of fatigue and Quality of Life of MS patients.
Conditions
Interventions
- DRUG
-
Melatonin
it is kind of drug
- DRUG
-
It is Placebo
Sponsors & Collaborators
-
Isfahan University of Medical Sciences
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-05-31
- Primary Completion
- 2012-10-31
- Completion
- 2012-10-31
Countries
- Iran
Study Locations
More Related Trials
-
Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)
NCT00594087 ·Status: COMPLETED ·Phase: NA
-
Sleep Medical Treatment in MS Patients Suffering From Fatigue
NCT03759249 ·Status: TERMINATED ·Phase: NA
-
Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients
NCT01516554 ·Status: TERMINATED ·Phase: PHASE2
-
Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation
NCT00342381 ·Status: COMPLETED ·Phase: PHASE2
-
Fatigue in MS: From Invisible to Measurable
NCT07182903 ·Status: COMPLETED
-
Ketamine for MS Fatigue
NCT06064162 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Self Help for Fatigue in Multiple Sclerosis
NCT01532037 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis
NCT03540485 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Open-Label Placebos to Treat Fatigue in Multiple Sclerosis
NCT04002102 ·Status: COMPLETED ·Phase: NA
-
ACTH for Fatigue in Multiple Sclerosis Patients
NCT02315872 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects
NCT02463318 ·Status: COMPLETED ·Phase: NA
-
Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects
NCT04699747 ·Status: RECRUITING ·Phase: PHASE1
-
Ketamine for Treatment of MS Fatigue
NCT03500289 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis
NCT01879202 ·Status: UNKNOWN ·Phase: PHASE2
-
Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)
NCT00981084 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Exercise to Manage Fatigue in Progressive Multiple Sclerosis
NCT04304027 ·Status: UNKNOWN ·Phase: NA
-
Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue
NCT03621761 ·Status: COMPLETED ·Phase: PHASE4
-
Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach
NCT03266965 ·Status: COMPLETED ·Phase: PHASE1
-
Testing the Effects of Methylphenidate on Multiple Sclerosis
NCT02286557 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis
NCT01377870 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Telerehabilitation in Multiple Sclerosis
NCT04979845 ·Status: UNKNOWN ·Phase: NA
-
Fatigue Management Programs for People With MS
NCT03550170 ·Status: COMPLETED ·Phase: NA
-
MS Symptom Management Study
NCT02474940 ·Status: COMPLETED ·Phase: NA
-
Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis
NCT05809414 ·Status: RECRUITING ·Phase: PHASE3
-
Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
NCT00300716 ·Status: COMPLETED ·Phase: PHASE2/PHASE3